AstraZeneca PLC · AZN · FY2026 Q2 · Calendar Q3 2026

AstraZeneca posts EPS beat as revenue narrowly misses estimate

AstraZeneca’s supplied results show earnings resilience, with EPS above consensus and revenue slightly below it. The investment case remains dependent on pipeline execution, launches, and offsetting portfolio and pricing pressures.

Why did AZN rise 0.2% after beating EPS estimates in FY2026 Q2?

Research this report with FN2. Free to start; review your question before sending.

Reported Before market openNYSEHealthcare $289.47B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $2.63 Consensus $2.50
EPS surprise +5.2% Reported versus consensus
Reported revenue $15.38B Consensus $15.44B
Revenue surprise -0.3% Reported versus consensus
Check the math in the surprise calculator >

Market reaction

prior-close to event-session close
Stock move +0.2% Event window
SPY move +0.0% Same window
Abnormal move +0.2% Stock minus SPY
Volume 1.4× Versus trailing sessions
Subsequent drift -1.7% Up to 20 sessions
AZNSPY benchmark

Ask FN2 about AZN FY2026 Q2

Choose a question to continue your research

Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.

Transcript intelligence

What changed

The current quarter delivered actual EPS of 2.63 versus 2.50 estimated and revenue of 15.384 billion versus 15.436 billion estimated. The supplied current-quarter transcript analysis was unavailable; prior-quarter analysis emphasized oncology and rare-disease growth, pipeline progress, and higher investment.

Guidance delta

A current-quarter guidance change is not available in the supplied analysis. Prior-quarter full-year guidance was described as maintained, with mid- to high-single-digit revenue growth and low double-digit EPS growth.

Key takeaways

  • EPS exceeded the supplied consensus estimate, while revenue was slightly below estimate.
  • The current transcript analysis was skipped because of a provider outage; no additional current-quarter management interpretation is supplied.
  • Prior analysis highlighted oncology and rare-disease growth, pipeline readouts, and planned manufacturing and pipeline investment.
  • The prior-quarter analysis identified portfolio, pricing, regulatory, and competitive pressures as risks.

Management priorities

  • Advance the clinical pipeline and upcoming launches identified in the prior analysis.
  • Expand manufacturing capacity and support pipeline investment.
  • Build growth in oncology, rare disease, respiratory and immunology, and emerging markets.

Follow AZN with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
AZN EPS earnings history estimate and actual scatter chart 9 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $0.74 Q4 '23 actual $0.73, match Q1 '24 estimate $0.95 Q1 '24 actual $1.03, beat Q2 '24 estimate $0.96 Q2 '24 actual $0.99, beat Q2 '25 estimate $2.16 Q2 '25 actual $2.18, beat Q3 '25 estimate $2.29 Q3 '25 actual $2.38, beat Q4 '25 estimate $2.18 Q4 '25 actual $2.12, miss Q1 '26 estimate $2.57 Q1 '26 actual $2.58, match Q2 '26 estimate $2.50 Q2 '26 actual $2.63, beat Q3 '26 estimate $2.60 Q3 '26 actual $2.79, beat Q4 '26 estimate $2.32 Q1 '27 estimate $2.71 Q2 '27 estimate $2.67 Q3 '27 estimate $3.07
Show less

Analyst Consensus ?

ConsensusHold40 ratings
Bullish1947.5%
Neutral1537.5%
Bearish615.0%

1 unmapped firm rating excluded from the percentages.

Analyst 52W Price Targets

$174.35Current
$156Low
$180Average
$216High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
UBS Buy NeutralUpgradeFeb 13, 2025
Erste Group Buy HoldUpgradeSep 11, 2024
TD Cowen Buy BuyMaintainAug 12, 2024
Argus Research Buy BuyMaintainMay 30, 2024
BMO Capital Outperform OutperformMaintainApr 26, 2024
Show 36 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $174.35. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
HSBCAnalyst unavailable$216$179.64 +23.9%Dec 10, 2025
Morgan StanleyAnalyst unavailable$206$180.34 +18.2%Dec 3, 2025
Berenberg BankLuisa Hector$194$141.64 +11.3%Jul 9, 2025
BMO CapitalEtzer Darout$176$162.38 +0.9%Nov 13, 2024
BMO CapitalEtzer Darout$178$159.88 +2.1%Sep 11, 2024
See 6 more

Track every rating change on AZN the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.…

Historical context

All AZN earnings

Healthcare peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
ASND Ascendis Pharma A/S FY2026 Q3 · Calendar Q4 2026 +38.7% +3.0% Ascendis Q3 growth broadens the story, while execution risks remain
ALC Alcon Inc. FY2026 Q3 · Calendar Q4 2026 +2.2% -2.3% Alcon holds FY outlook as new launches meet IOL competition

Latest beats and misses

Who reports next

Get the AZN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-28T23:41:33.134213+00:00
  2. FN2 earnings calendar · 2026-09-01T01:23:15.986970+00:00
  3. Polygon adjusted daily market bars · 2026-10-31T18:50:43.143244+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-31T18:50:43.140501+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.